Emergent Biosolutions
EBS
183 hedge funds and large institutions have $336M invested in Emergent Biosolutions in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 75 reducing their positions, and 28 closing their positions.
2.31% more ownership
Funds ownership: 88.31% → 90.62% (+2.3%)
4% less funds holding
Funds holding: 191 → 183 (-8)
21% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 75
25% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 28
28% less capital invested
Capital invested by funds: $465M → $336M (-$129M)
30% less call options, than puts
Call options by funds: $1.02M | Put options by funds: $1.47M
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$12.9M |
| 2 |
Millennium Management
New York
|
+$8.13M |
| 3 |
Man Group
London,
United Kingdom
|
+$4.17M |
| 4 |
PGCM
Prescott Group Capital Management
Tulsa,
Oklahoma
|
+$2.85M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$2.67M |
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$10.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$4.12M |
| 3 |
D.E. Shaw & Co
New York
|
-$3.58M |
| 4 |
First Trust Advisors
Wheaton,
Illinois
|
-$3.46M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.98M |
EBS Hedge Fund Activity: Q2 2023 in Review
183 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q2 2023, worth a combined $336M — down 28% from $465M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of EBS and 21 opened new positions — a net loss of 7 holders — while 75 trimmed existing stakes and 59 added.
The largest buyer was State Street, adding an estimated $12.9M. The largest seller was Vanguard Group, cutting an estimated $10.1M.
- 183 institutional investors held Emergent Biosolutions (EBS) as of Q2 2023, down from 191 in Q1 2023.
- Funds reported $336M of Emergent Biosolutions stock for Q2 2023, down 28% quarter-over-quarter.
- 21 funds opened new Emergent Biosolutions positions in Q2 2023 and 28 closed out, a net change of -7 holders.
- The largest Emergent Biosolutions buyer in Q2 2023 was State Street, an estimated $12.9M added.
- The largest Emergent Biosolutions seller in Q2 2023 was Vanguard Group, an estimated $10.1M sold.
Based on aggregated 13F filings for Q2 2023.